Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report
Abstract
:1. Introduction
2. Case Report
3. Pharmacokinetic Profile
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Wilhelm, M.P. Vancomycin. Mayo Clin. Proc. 1991, 66, 1165–1170. [Google Scholar] [CrossRef] [PubMed]
- De Hoog, M.; Mouton, J.W.; van den Anker, J.N. Vancomycin: Pharmacokinetics and administration regimens in neonates. Clin. Pharmacokinet. 2004, 43, 417–440. [Google Scholar] [CrossRef] [PubMed]
- U.S. FDA. Guidance for Industry: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products; U.S. Food and Drug Administration: Silver Spring, MD, USA, 1998. Available online: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072114.pdf (accessed on 15 August 2022).
- Gijsen, M.; Vlasselaers, D.; Spriet, I.; Allegaert, K. Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine. Antibiotics 2021, 10, 1182. [Google Scholar] [CrossRef] [PubMed]
- Fletcher, K.; Chapman, R.; Keene, S. An overview of medical ECMO for neonates. Semin. Perinatol. 2018, 42, 68–79. [Google Scholar] [CrossRef]
- Buck, M.L. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1998, 18, 1082–1086. [Google Scholar] [PubMed]
- Hahn, J.; Choi, J.H.; Chang, M.J. Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients. J. Clin. Pharm. Ther. 2017, 42, 661–671. [Google Scholar] [CrossRef] [Green Version]
- An, S.H.; Lee, E.M.; Kim, J.Y.; Gwak, H.S. Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation. Eur. J. Hosp. Pharm. 2020, 27, e25–e29. [Google Scholar] [CrossRef] [Green Version]
- Moffett, B.S.; Morris, J.; Galati, M.; Munoz, F.; Arikan, A.A. Population Pharmacokinetics of Vancomycin in Pediatric Extracorporeal Membrane Oxygenation. Pediatr. Crit. Care Med. 2018, 19, 973–980. [Google Scholar] [CrossRef]
- Schwartz, G.J.; Haycock, G.B.; Edelmann, C.M., Jr.; Spitzer, A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976, 58, 259–263. [Google Scholar] [CrossRef]
- Schwartz, G.J.; Feld, L.G.; Langford, D.J. A simple estimate of glomerular filtration ratein full-term infants during the first year of life. J. Pediatr. 1984, 104, 849–854. [Google Scholar] [CrossRef]
- Villa, G.; Katz, N.; Ronco, C. Extracorporeal Membrane Oxygenation and the Kidney. Cardiorenal Med. 2015, 6, 50–60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Winter, M.E. Basic Clinical Pharmacokinetics, 4th ed.; Technomics, Inc.: Tokyo, Japan, 2005; p. 55. [Google Scholar]
- Hoie, E.B.; Swigart, S.A.; Leuschen, M.P.; Willett, L.D.; Bolam, D.L.; Goodrich, P.D.; Bussey, M.E.; Nelson, R.M., Jr. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin. Pharm. 1990, 9, 711–715. [Google Scholar] [PubMed]
- Pokorná, P.; Šíma, M.; Tibboel, D.; Slanař, O. Impact of haemolysis on vancomycin disposition in a full-term neonate treated with extracorporeal membrane oxygenation. Perfusion 2021, 36, 864–867. [Google Scholar] [CrossRef]
- Amaker, R.D.; DiPiro, J.T.; Bhatia, J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob. Agents Chemother. 1996, 40, 1139–1142. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Friis-Hansen, B. Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth. Pediatrics 1971, 47 (Suppl S2), 264+. [Google Scholar]
- Smith, A.H.; Hardison, D.C.; Worden, C.R.; Fleming, G.M.; Taylor, M.B. Acute renal failure during extracorporeal support in the pediatric cardiac patient. ASAIO J. 2009, 55, 412–416. [Google Scholar] [CrossRef]
- Lu, H.; Rosenbaum, S. Developmental pharmacokinetics in pediatric populations. J. Pediatr. Pharmacol. Ther. 2014, 19, 262–276. [Google Scholar] [CrossRef]
- Donadello, K.; Roberts, J.A.; Cristallini, S.; Beumier, M.; Shekar, K.; Jacobs, F.; Belhaj, A.; Vincent, J.L.; de Backer, D.; Taccone, F.S. Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: A matched cohort study. Crit. Care 2014, 18, 632. [Google Scholar] [CrossRef] [Green Version]
- Young, D.G. Fluid balance in paediatric surgery. Br. J. Anaesth. 1973, 45, 953–957. [Google Scholar] [CrossRef] [Green Version]
- Sherwin, J.; Heath, T.; Watt, K. Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature. Clin. Ther. 2016, 38, 1976–1994. [Google Scholar] [CrossRef] [Green Version]
- Bartlett, R.H. Extracorporeal life support for cardiopulmonary failure. Curr. Probl. Surg. 1990, 27, 621–705. [Google Scholar] [CrossRef] [PubMed]
- Rybak, M.J.; Le, J.; Lodise, T.P.; Levine, D.P.; Bradley, J.S.; Liu, C.; Mueller, B.A.; Pai, M.P.; Wong-Beringer, A.; Rotschafer, J.C.; et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 2020, 77, 835–864. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mulubwa, M.; Griesel, H.A.; Mugabo, P.; Dippenaar, R.; van Wyk, L. Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates. Drugs R&D 2020, 20, 105–113. [Google Scholar] [CrossRef] [Green Version]
- Cohen, P.; Collart, L.; Prober, C.G.; Fischer, A.F.; Blaschke, T.F. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr. Infect. Dis. J. 1990, 9, 562–566. [Google Scholar] [CrossRef]
- Bhatt-Mehta, V.; Johnson, C.E.; Schumacher, R.E. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1992, 12, 28–32. [Google Scholar] [PubMed]
- Southgate, W.M.; DiPiro, J.T.; Robertson, A.F. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob. Agents Chemother. 1989, 33, 817–819. [Google Scholar] [CrossRef] [Green Version]
- Munzenberger, P.J.; Massoud, N. Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans. 1991, 37, 16–18. [Google Scholar] [CrossRef]
- Kato, H.; Hagihara, M.; Okudaira, M.; Asai, N.; Koizumi, Y.; Yamagishi, Y.; Mikamo, H. Systematic review and meta-analysis to explore optimal therapeutic range of vancomycin trough level for infected paediatric patients with Gram-positive pathogens to reduce mortality and nephrotoxicity risk. Int. J. Antimicrob. Agents. 2021, 58, 106393. [Google Scholar] [CrossRef]
- Uda, K.; Suwa, J.; Ito, K.; Hataya, H.; Horikoshi, Y. Ototoxicity and Nephrotoxicity with Elevated Serum Concentrations Following Vancomycin Overdose: A Retrospective Case Series. J. Pediatr. Pharmacol. Ther. 2019, 24, 450–455. [Google Scholar] [CrossRef]
- Lutsar, I.; Metsvaht, T. Understanding pharmacokinetics/pharmacodynamics in managing neonatal sepsis. Curr. Opin. Infect. Dis. 2010, 23, 201–207. [Google Scholar] [CrossRef]
X−4 | X−3 | X | X+1 | X+2 | X+3 | X+4 | X+5 | X+6 | X+7 | X+8 | X+9 | X+10 | X+11 | X+12 | X+13 | X+14 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasma free Hb, g/L | 0.08 | 0.08 | 0.06 | 0.06 | 0.09 | 0.13 | 0.03 | 0.05 | 0.09 | 0.09 | |||||||
SCr, mg/dL | 0.2 | 0.4 | 0.5 | 0.5 | 0.3 | 0.3 | 0.3 | 0.5 | 0.6 | 0.7 | 0.6 | 0.6 | 0.6 | 0.4 | 0.3 | 0.3 | 0.3 |
GFR, mL/min/1.73 m2 | 138.4 | 69.2 | 55.4 | 55.4 | 92.3 | 92.3 | 92.3 | 55.4 | 46.1 | 39.5 | 46.1 | 46.1 | 46.1 | 69.2 | 92.3 | 92.3 | 92.3 |
BUN, mg/dL | 10.9 | 11.2 | 45.7 | 70.8 | 67.3 | 72.4 | 78.2 | 85.3 | 90.2 | 91.6 | 104.9 | 109.3 | 99.3 | 107.8 | 88.7 | 80.0 | 75.0 |
AST, IU | 29 | 55 | 122 | 115 | 79 | 73 | 74 | 43 | 86 | 100 | 151 | 57 | 51 | 49 | 75 | ||
ALT, IU | 25 | 16 | 34 | 26 | 23 | 19 | 20 | 13 | 21 | 30 | 43 | 53 | 50 | 56 | 57 | 58 | 58 |
Thrombocytes, 103/µL | 276 | 194 | 53 | 31 | 77 | 120 | 121 | 197 | 167 | 280 | 172 | 64 | 51 | 121 | 119 | 106 | 107 |
Total bilirubin, mg/dL | 0.2 | 2.2 | 2.4 | 3.9 | 2.3 | 2.8 | 2.8 | 1.5 | 2.5 | 4.4 | 4.7 | 4.6 | 4.2 | 3.7 | 2.9 | 2.0 | 1.6 |
Serum potassium, mmol/L | 4.5 | 4.7 | 4.9 | 3.8 | 3.6 | 3.7 | 3.5 | 4.1 | 4.6 | 5.0 | 5.0 | 4.3 | 4.4 | 3.9 | 4.3 | 3.2 | 3.2 |
CRP, mg/dL | 1.1 | 1.1 | 6.2 | 3.0 | 2.0 | 2.7 | 5.8 | 6.6 | 22.7 | 25.8 | 21.8 | 12.2 | 15.3 | 11.3 | 8.0 | 6.4 | 5.7 |
PCT, ng/mL | 2.5 | 1.5 | 0.4 | >75.0 | >75.0 | 73.3 | 71.8 | 42.7 | 19.6 | 8.0 | 7.8 | ||||||
BT, °C | 37.2 | 36.8 | 36.9 | 36.5 | 36.3 | 36.7 | 36.7 | 36.6 | 36.6 | 37.3 | 35.7 | 37.1 | 37.1 | 36.5 | 36.8 | 36.3 | 36.3 |
Urine volume, mL/day | 618 | 244 | 239 | 607 | 554 | 528 | 363 | 241 | 744 | 816 | 544 | 625 | 603 | 543 | 484 | 207 | 501 |
WBC, 103/µL | 8.8 | 3.5 | 9.5 | 7.3 | 10.5 | 9.0 | 8.6 | 11.2 | 16.9 | 17.3 | 16.3 | 20.2 | 20.8 | 21.9 | 22.1 | 19.4 | 18.6 |
VCM dose | |||||||||||||||||
165 mg/day every 8 h (37.7 mg/kg/day) | ○ | ○ | ○ | ○ | |||||||||||||
80 mg/day every 12 h (18.2 mg/kg/day) | ○ | ||||||||||||||||
40 mg/day every 24 h (9.1 mg/kg/day) | ○ | ○ | ○ | ○ | ○ | ○ | |||||||||||
VCM concentration, μg/mL | 27.1 | 18.6 | 36.1 | 22.4 | |||||||||||||
ECMO | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ||||||
Rotational frequency, rpm | 2010 | 2010 | 2010 | 2010 | 2010 | 1430 | 1770 | 1770 | 1640 | 1770 | 1570 | ||||||
Blood volume, L/min | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.2 | 0.2 | 0.2 | 0.1 | 0.3 | 0.1 | ||||||
Oxygen flow rate, L/min | 0.4 | 0.3 | 0.3 | 0.1 | 0.2 | 0.1 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shiraishi, C.; Kato, H.; Imai, H.; Iwamoto, T. Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report. Int. J. Environ. Res. Public Health 2023, 20, 1839. https://doi.org/10.3390/ijerph20031839
Shiraishi C, Kato H, Imai H, Iwamoto T. Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report. International Journal of Environmental Research and Public Health. 2023; 20(3):1839. https://doi.org/10.3390/ijerph20031839
Chicago/Turabian StyleShiraishi, Chihiro, Hideo Kato, Hiroshi Imai, and Takuya Iwamoto. 2023. "Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report" International Journal of Environmental Research and Public Health 20, no. 3: 1839. https://doi.org/10.3390/ijerph20031839